The FDA’s refuse-to-file letter cited no safety or efficacy concerns for Moderna’s influenza vaccine, mRNA-1010. The company said the agency’s justification for refusing a review is inconsistent with ...

Telepsychiatry provider Talkiatry has raised a $210 million Series D round led by Perceptive Advisors, bringing its total funding to more than $400 million. CEO Robert Krayn said the company is ...

OpenEvidence’s $12 billion valuation reflects investor confidence in its bottom-up, doctor-first model. It has driven rapid adoption, with more than 757,000 clinicians using the startup’s free AI ...

NYU Langone Health is partnering with Isaac Health to launch a specialist-led virtual care model aimed at reducing long waits for memory care. The partnership will test whether telehealth can expand ...

Health advocate network Solace Health gained unicorn status after closing a $130 million Series C funding round. The startup’s advocates help with tasks like scheduling appointments, finding ...

A BridgeBio Pharma drug developed for dwarfism increased children’s growth rates in a pivotal clinical trial, meeting the study’s main goal and boosting the daily pill’s chances to offer an ...

The next frontier for cell therapy is shaping up to be in vivo treatments for autoimmune disease, and Eli Lilly is getting a contender through the acquisition of startup Orna Therapeutics for up to $2 ...

Several years ago, during a budget review at a Medicare Advantage organization I led, our finance team flagged a familiar problem: medical costs were rising faster than projected revenue. On paper, ...

When Evommune went public late last year, it said data from a proof-of-concept test of one of its atopic dermatitis drug candidates would come in the first half of 2026. The results are in, with the ...

Small medical practices are often described as the backbone of the U.S. healthcare system. They deliver accessible, community-based care and build long-term relationships with patients. Yet behind the ...

Technology is changing the way pharmaceutical companies discover and develop new drugs. For Matt Studney, who joined Merck as a chemical engineer, technology changed the course of his career. In 2017, ...